Product Code: GVR-1-68038-194-8
Pneumatic Nebulizers Market Growth & Trends:
The global pneumatic nebulizers market size is expected to reach USD 1,166.74 million by 2030, registering a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has shown constant growth in the adoption of pneumatic nebulizers as home healthcare devices have been gaining popularity in recent years. Miniaturization of products and technological advancements are also boosting the adoption of home healthcare devices.
As per the Minnesota Department of Health, administration of medication through nebulizer represents a lower infection risk as compared to other aerosol-producing procedures. On the other hand, according to ISAM, aerosols from the nebulizer do not carry viral particles derived from the patient as they are generated from the fluid in the nebulized chamber, which is a non-patient source. Aerosols generated by nebulizers comprise pathogens only when the healthcare workers or patients contaminate the nebulizers. Various recommendations from institutes do not clarify whether it is appropriate to use nebulizers during the pandemic.
However, there are no known cases of passive infection due to nebulizers. Also, the risk of infection, if any, can be avoided if proper COVID-19 precautions are taken. Therefore, the pandemic affected the overall market only to a certain extent. Revolutionary technological progress is rapidly transforming the market. These expansions are producing lucrative potentials. For instance, in March 2019, Breath Technologies announced the initiation of Phase 3 BOSTON clinical study of L-CsA-i for the treatment of bronchiolitis obliterans syndrome via a drug-specific eFlow nebulizer of PARI Pharma that is under investigation.
Pneumatic Nebulizers Market Report Highlights:
- Based on indication, the breath-actuated segment held the largest revenue share 64.06% in 2024. Breath-actuated nebulizers elucidate higher drug delivery capacity and lesser dosage wastage features. Thus, the segment delivering advanced inhalation therapy is expected to dominate the market over the forecast period.
- Hospitals & clinics segment held the largest market share in 2024. The increasing adoption of pneumatic nebulizers for the management of acute respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) is fueling the segment growth.
- North America pneumatic nebulizers market dominated with a revenue share of 35.28% in 2024 and is poised to grow over the forecast period owing to the increasing prevalence of respiratory diseases and advancements in nebulizer technology.
- Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The burden of COPD in Asia is greater than that in developed Western countries.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Indication
- 1.2.2. End Use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.2.5. Industry Analysis - Porter's Five Forces Analysis
- 3.2.5.1. Supplier power
- 3.2.5.2. Buyer power
- 3.2.5.3. Substitution threat
- 3.2.5.4. Threat of new entrant
- 3.2.5.5. Competitive rivalry
- 3.2.6. PESTLE Analysis
Chapter 4. Indication Business Analysis
- 4.1. Indication Market Share, 2024 & 2030
- 4.2. Indication Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
- 4.4. Breath-actuated
- 4.4.1. Breath-actuated market, 2018 - 2030 (USD Million)
- 4.5. Vented
- 4.5.1. Vented market, 2018 - 2030 (USD Million)
Chapter 5. End Use Business Analysis
- 5.1. End Use Market Share, 2024 & 2030
- 5.2. End Use Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 5.4. Hospitals & Clinics
- 5.4.1. Hospitals & clinics market, 2018 - 2030 (USD Million)
- 5.5. Home Healthcare
- 5.5.1. Home healthcare market, 2018 - 2030 (USD Million)
Chapter 6. Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2024 & 2030
- 6.2. Regional Market Dashboard
- 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.4. North America
- 6.4.1. North America pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.2. U.S.
- 6.4.2.1. Key country dynamic
- 6.4.2.2. Regulatory framework/reimbursement scenario
- 6.4.2.3. U.S. pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Canada
- 6.4.3.1. Key country dynamic
- 6.4.3.2. Regulatory framework/reimbursement scenario
- 6.4.3.3. Canada pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.4. Mexico
- 6.4.4.1. Key country dynamic
- 6.4.4.2. Regulatory framework/reimbursement scenario
- 6.4.4.3. Mexico pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5. Europe
- 6.5.1. Europe pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.2. UK
- 6.5.2.1. Key country dynamic
- 6.5.2.2. Regulatory framework/reimbursement scenario
- 6.5.2.3. UK pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Germany
- 6.5.3.1. Key country dynamic
- 6.5.3.2. Regulatory framework/reimbursement scenario
- 6.5.3.3. Germany pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.4. France
- 6.5.4.1. Key country dynamic
- 6.5.4.2. Regulatory framework/reimbursement scenario
- 6.5.4.3. France pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.5. Italy
- 6.5.5.1. Key country dynamic
- 6.5.5.2. Regulatory framework/reimbursement scenario
- 6.5.5.3. Italy pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.6. Spain
- 6.5.6.1. Key country dynamic
- 6.5.6.2. Regulatory framework/reimbursement scenario
- 6.5.6.3. Spain pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.7. Norway
- 6.5.7.1. Key country dynamic
- 6.5.7.2. Regulatory framework/reimbursement scenario
- 6.5.7.3. Norway pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.8. Denmark
- 6.5.8.1. Key country dynamic
- 6.5.8.2. Regulatory framework/reimbursement scenario
- 6.5.8.3. Denmark pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.9. Sweden
- 6.5.9.1. Key country dynamic
- 6.5.9.2. Regulatory framework/reimbursement scenario
- 6.5.9.3. Sweden pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6. Asia Pacific
- 6.6.1. Asia Pacific pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Japan
- 6.6.2.1. Key country dynamic
- 6.6.2.2. Regulatory framework/reimbursement scenario
- 6.6.2.3. Japan pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6.3. China
- 6.6.3.1. Key country dynamic
- 6.6.3.2. Regulatory framework/reimbursement scenario
- 6.6.3.3. China pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6.4. India
- 6.6.4.1. Key country dynamic
- 6.6.4.2. Regulatory framework/reimbursement scenario
- 6.6.4.3. India pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6.5. South Korea
- 6.6.5.1. Key country dynamic
- 6.6.5.2. Regulatory framework/reimbursement scenario
- 6.6.5.3. South Korea pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6.6. Australia
- 6.6.6.1. Key country dynamic
- 6.6.6.2. Regulatory framework/reimbursement scenario
- 6.6.6.3. Australia pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6.7. Thailand
- 6.6.7.1. Key country dynamic
- 6.6.7.2. Regulatory framework/reimbursement scenario
- 6.6.7.3. Thailand pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7. Latin America
- 6.7.1. Latin America pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7.2. Brazil
- 6.7.2.1. Key country dynamic
- 6.7.2.2. Regulatory framework/reimbursement scenario
- 6.7.2.3. Brazil pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7.3. Argentina
- 6.7.3.1. Key country dynamic
- 6.7.3.2. Regulatory framework/reimbursement scenario
- 6.7.3.3. Argentina pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.8. MEA
- 6.8.1. MEA pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.8.2. South Africa
- 6.8.2.1. Key country dynamic
- 6.8.2.2. Regulatory framework/reimbursement scenario
- 6.8.2.3. South Africa pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.8.3. Saudi Arabia
- 6.8.3.1. Key country dynamic
- 6.8.3.2. Regulatory framework/reimbursement scenario
- 6.8.3.3. Saudi Arabia pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.8.4. UAE
- 6.8.4.1. Key country dynamic
- 6.8.4.2. Regulatory framework/reimbursement scenario
- 6.8.4.3. UAE pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.8.5. Kuwait
- 6.8.5.1. Key country dynamic
- 6.8.5.2. Regulatory framework/reimbursement scenario
- 6.8.5.3. Kuwait pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Participant Overview
- 7.2. Company Market Position Analysis
- 7.3. Company Categorization
- 7.4. Strategy Mapping
- 7.5. Company Profiles/Listing
- 7.5.1. Koninklijke Philips N.V.
- 7.5.1.1. Overview
- 7.5.1.2. Financial performance
- 7.5.1.3. Product benchmarking
- 7.5.1.4. Strategic initiatives
- 7.5.2. OMRON Corporation
- 7.5.2.1. Overview
- 7.5.2.2. Financial performance
- 7.5.2.3. Product benchmarking
- 7.5.2.4. Strategic initiatives
- 7.5.3. Cook Medical PARI GmbH
- 7.5.3.1. Overview
- 7.5.3.2. Financial performance
- 7.5.3.3. Product benchmarking
- 7.5.3.4. Strategic initiatives
- 7.5.4. General Electric
- 7.5.4.1. Overview
- 7.5.4.2. Financial performance
- 7.5.4.3. Product benchmarking
- 7.5.4.4. Strategic initiatives
- 7.5.5. Allied Healthcare Products, Inc.
- 7.5.5.1. Overview
- 7.5.5.2. Financial performance
- 7.5.5.3. Product benchmarking
- 7.5.5.4. Strategic initiatives
- 7.5.6. BD (Becton, Dickinson & Company)
- 7.5.6.1. Overview
- 7.5.6.2. Financial performance
- 7.5.6.3. Product benchmarking
- 7.5.6.4. Strategic initiatives
- 7.5.7. GF Health Products, Inc.
- 7.5.7.1. Overview
- 7.5.7.2. Financial performance
- 7.5.7.3. Product benchmarking
- 7.5.7.4. Strategic initiatives
- 7.5.8. Medline Industries, LP
- 7.5.8.1. Overview
- 7.5.8.2. Financial performance
- 7.5.8.3. Product benchmarking
- 7.5.8.4. Strategic initiatives
- 7.5.9. Briggs Healthcare
- 7.5.9.1. Overview
- 7.5.9.2. Financial performance
- 7.5.9.3. Product benchmarking
- 7.5.9.4. Strategic initiatives
- 7.5.10. Vectura Group Ltd
- 7.5.10.1. Overview
- 7.5.10.2. Financial performance
- 7.5.10.3. Product benchmarking
- 7.5.10.4. Strategic initiatives